KEY POINTS 1) The HIF inhibitor acriflavine suppresses TKi-insensitive CML stem cells.
INTRODUCTION
Chronic myeloid leukemia (CML), a clonal disease affecting hematopoietic stem cells (HSC), is driven by the 9;22(q34.1;q11.2) chromosomal translocation, which results in the expression of BCR/Abl oncoprotein, a constitutively-active tyrosine kinase. Chronic-phase CML patients are treated with tyrosine kinase inhibitors (TKi) targeting BCR/Abl, such as imatinib-mesylate (IM). 1 Successful TKi therapy leads in most cases, rather than to CML cure, to a state of minimal residual disease, apparently sustained by the persistence of TKi-resistant leukemia stem cells (LSC). [2] [3] [4] [5] [6] Thus, the search for drugs capable of targeting these cells is of primary importance in order to eradicate CML.
In bone marrow (BM), LSC most likely reside in stem cell niches located within tissue areas at very low oxygen tension, where HSC are physiologically hosted. 7, 8 Studies from our group 9-11 and others 12,13 demonstrated that low oxygen maintains HSC survival and stem cell potential, favoring
Colony Formation Ability (CFA) assay
CML patient-derived BMMC (2.5-5.0x10 4 ), or CD34-enriched PBMC from healthy donors (0.5-
1.0x10
3 ) were suspended in IMDM containing 2% FBS, 100 units/ml penicillin/streptomycin. Cells were plated in methyl-cellulose-containing medium (#04435, Stem Cell Technology, Vancouver, BC, Canada) in 35-mm dishes, treatments were applied at time 0 and colonies were counted after 7, 14 or 21 days of incubation. Colony formation efficiency was calculated dividing the number of colonies scored by the number of cells plated. In some experiments, cells were serially replated after 7 or 14 days of culture.
Long Term Culture-Initiating Cell (LTC-IC) assay
BMMC from CML patients were drug-treated in low oxygen for 2 days, resuspended in human long-term medium (HLTM, Myelocult #05100, Stem Cell Technology) supplemented with hydrocortisone (10 -6 M) and plated onto irradiated (8000 cGy) M2-10B4 cells in collagen-coated 35-mm dishes. Half of medium was replaced weekly. After 5 weeks, cells were replated (5x10 4 /35-mm dish) in methyl-cellulose-containing medium (#04435, Stem Cell Technology) and colonies scored after 14 days.
Mice
C57BL/6J-CD45.1 mice (The Jackson Laboratory, Bar Harbor, ME, U.S.A) were handled in accordance with protocols and regulations approved by the IACUC of University of Massachusetts Medical School. CML mice were treated daily with ACF (8 mg/kg) or PBS via intraperitoneal injection, for 10 days starting from day 7 after bone marrow transplantation.
Murine CML model
Retroviruses were prepared and CML induced in mice as previously described. 
Flow cytometry
Apoptosis was quantified in K562 or KCL22 cells by annexin V-APC (#31490016; Immunotools;
Friesoythe, Germany), following the manufacturer's instructions. Murine BM or PB cells were incubated with red blood cell lysis buffer, washed, resuspended in PBS and antibody-labelled 
Statistical analyses
Statistical analysis for pairwise comparisons was performed using Student's t test for paired samples (data following a normal distribution), while that for multiple comparisons was performed by ANOVA, when values followed normal distribution, or nonparametric tests, using GraphPad software (La Jolla, CA, U.S.A.). A p value less than 0.05 was considered statistical significant.
RESULTS

Acriflavine reduces cell number, c-MYC expression and stem cell potential in CML cells.
We evaluated the effects of CML cell incubation in low oxygen on HIF-1α expression and activity. We found that HIF-1α protein is expressed in primary and stabilized CML cells in normoxia ( Figure 1A ), as observed in other blood cancers. 40 Nevertheless, in K562 or KCL22 cells, the expression of nuclear HIF-1α protein increased in low oxygen ( Figure 1B ). Hypoxia also increased HIF-1α activity, as indicated by the enhanced expression of carbonic anhydrase 9 (CAIX) and vascular-endothelial growth factor (VEGF), both encoded for by HIF-1α-targeted genes ( Figure   1C ). To identify drugs suitable for HIF-1α targeting in CML cells, we tested two HIF inhibitors with different mechanism of action. ACF, but not YC1 ( Figure 1D ), at concentrations around IC50
( Figure S1A ), inhibited the increase of CAIX and VEGF mRNA induced by a 2-day incubation in low oxygen. ACF or YC1 did not reduce HIF-1α mRNA, in agreement with their mechanisms of action. These results suggested that the reduction of viable cell number determined by YC1 in low oxygen ( Figure S1A ,B) was due to effects different from the inhibition of transcriptional activity of HIF-1α. Thus, we decided to use ACF for further investigations.
ACF treatment reduced the number of viable KCL22 or K562 cells in low oxygen (Figure 2A ), an effect paralleled by the induction of apoptosis ( Figure 2B ,C). The anti-proliferative effect of ACF was supported by the fact that ACF suppressed the expression of c-MYC ( Figure 2D ), a protooncogene important for cell cycle regulation and BCR/Abl-driven transformation. 41,42 ACF inhibited c-MYC expression at the transcriptional (data not shown) and protein expression levels, exhibiting in the latter case higher efficiency than IM. We previously demonstrated that leukemia cell lines, including CML lines, are functionally heterogeneous and comprise cell subsets endowed with different stem/progenitor cell potential. Such a heterogeneity emerged following incubation in low oxygen. 4, 5, 14 On this basis, using K562 and KCL22 cells, we tested the effects of ACF on the maintenance of CML stem cell potential in low oxygen ( Figure 2E ). Cells were drug-treated or not (PBS addition) from time 0 in primary cultures (LC1) in low oxygen and transferred on day 7 to drug-free secondary cultures (LC2) incubated in normoxia, to exploit their repopulation potential.
LC2 repopulation was indeed used as a read-out of maintenance of stem cell potential in LC1. This assay is an in vitro cognate of the marrow repopulation assay (see M&M). 16, 36, 37 It is worth noting here that around 1% of cells rescued from a 7-day incubation in low-oxygen LC1 is responsible for LC2 repopulation (data not shown). Untreated LC1 cells repopulated LC2 after a 7-10 day lagphase as previously reported. 4,5 LC2 repopulation was abolished by ACF ( Figure 2E ). To exclude that the lack of LC2 repopulation was due to residual ACF from LC1, we measured the amount of ACF in LC2 culture medium by LC-MS/MS (Supplemental Methods). ACF concentration resulted 81.3±4.6 nM (vs 5 μM at time 0 of LC1). Such a concentration was found unable to affect growth kinetics of K562 or KCL22 cells ( Figure S2 ).
In contrast to ACF, YC1 was ineffective in preventing LC2 repopulation ( Figure S1C ), likely because of its inefficacy in inhibiting HIF-1α activity ( Figure 1D ). The effect of HIF-1α inhibition in abolishing LC2 repopulation was confirmed in K562 cells by shRNA ( Figure 2F ). Finally, the effects of ACF on the maintenance of stem cell potential in low-oxygen culture were tested under conditions likely to better mimic the in vivo scenario, where LSC are adapted to the low-oxygen stem cell niche before the beginning of drug treatment. Thus, ACF was administered to K562 or KCL22 cultures at day 6 of incubation in low oxygen, and cells were transferred to LC2 at day 9.
ACF suppressed LC2 repopulation, indicating that a previous LSC adaptation to low oxygen did not reduce the drug's effectiveness on stem cell potential ( Figure 2G ). We also determined in K562 cells the effects of low oxygen and ACF treatment on stemness-related genes, such as NANOG, OCT4 and SOX2 ( Figure S3 ). The expression of these genes was markedly increased in low oxygen 43 and ACF treatment reduced this increase. Thus, low oxygen boosts stem cell potential, which is targeted by ACF.
As TKi represent a consolidated standard for CML therapy, it was important to determine whether the combination with ACF could affect the action of IM negatively and vice versa ( Figure   3 ). K562 or KCL22 cells were incubated in low oxygen for 3 days in the absence or presence of ACF or IM or their combination. As expected, IM reduced the number of viable cells in culture.
Interestingly, drug combination enhanced the effects of single-drug treatments ( Figure 3A) .
Furthermore, cells incubated in low oxygen and treated as above were transferred to normoxic LC2 on day 7. Despite its effect on cell bulk, IM did not affect LC2 repopulation ( Figure 3B ), as we previously reported, 4,5 in keeping with the refractoriness of LSC to TKi. The effects of ACF in the inhibition of stem cell potential of primary CML cells were confirmed using serial CFA and LTC-IC assays. ACF, alone or in combination with IM, reduced replating efficiency in all patients. On the contrary, IM, in two out of three patients, not only did not reduce, but actually enhanced CFA starting from tertiary cultures ( Figure 5A ). In the highly stringent LTC-IC assay, ACF, differently from IM, was strongly effective ( Figure 5B ).
Acriflavine reduces CML development and LSC maintenance in vivo.
The effects of ACF were tested in vivo using mice transplanted with BCR/abl-transduced BM we found that the latter were significantly less sensitive to ACF, as far as total PB or BM cells or CD34+/LSK are concerned. This is well in keeping with the less severe addiction to HIF-1α of HSC when compared to LSC. 21 Finally, ACF was well tolerated by un-manipulated (non-BCR/abltransduced) mice even when administered at doses higher than that used for the experiments reported in this study (data not shown). This points to a good therapeutic index of ACF in discriminating leukemic from normal hematopoietic cells.
On the basis of all above, ACF emerges as a good candidate to target at one time CML cell bulk and LSC, thus inducing remission and preventing late relapse of disease. It is worth noting that ACF is an already FDA-approved drug for non-oncological uses in humans, 22 and that ACF was administered to patients for at least 5 months without major adverse effects. 62 Thus, we propose ACF as a novel therapeutic approach to prevent CML relapse and, in combination with TKi, to enhance induction of remission. 
